Nalaganje...
Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: implications for targeted therapy development
BACKGROUND: Erlotinib is a standard first-line therapy for metastatic non-small-cell lung cancers (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The recommended dose of 150mg daily is the maximum tolerated dose (MTD). Little clinical data is available regarding its efficacy at doses...
Shranjeno v:
| izdano v: | Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5311035/ https://ncbi.nlm.nih.gov/pubmed/27525836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30270 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|